Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against KDDI Corporation, focusing on possible violations of federal securities laws by the company and its senior management [1] Group 1: Investigation Details - The investigation was prompted by KDDI's announcement on February 6, 2026, regarding the postponement of its earnings report for the third quarter of the fiscal year ending March 2026, citing uncertainties related to quarterly results and an internal investigation [1] - Following the announcement, KDDI's share price fell by $2.03, or approximately 11.44%, from $17.74 on February 5, 2026, to close at $15.71 on February 6, 2026 [1] Group 2: Legal Context - No lawsuit has been filed yet, and the investigation is ongoing to determine if claims can be brought under federal securities laws [1] - Investors who purchased or acquired KDDI securities are encouraged to contact Kirby McInerney LLP for more information regarding their rights or interests related to the investigation [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. (NASDAQ: QURE) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Summary by Relevant Sections Company Overview - uniQure N.V. is facing allegations of violating federal securities laws by making false or misleading statements regarding its Pivotal Study and the approval status of its BLA submission for AMT-130 [1] Legal Proceedings - The complaint alleges that the design of uniQure's Pivotal Study was not fully approved by the FDA, and that the company downplayed the likelihood of needing to delay its BLA timeline for additional studies [1] - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that data from the Phase I/II AMT-130 studies would support a BLA submission, leading to a significant drop in share price [1] Financial Impact - Following the disclosure, uniQure's share price fell by $33.40, or over 49%, from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1]

Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit on behalf of shareholders of uniQure N.V. (NASDAQ: QURE) due to allegations of misleading investors regarding the company's business operations and the approval status of its pivotal study for a drug candidate targeting Huntington's Disease [1] Group 1: Allegations Against uniQure N.V. - The lawsuit claims that uniQure misrepresented the approval status of its pivotal study by the U.S. Food and Drug Administration (FDA) [1] - It is alleged that the company downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline to conduct additional studies [1] - The lawsuit asserts that the statements made by uniQure regarding its business, operations, and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [1] Group 2: Class Action Participation - Shareholders who wish to serve as lead plaintiffs must file their motions by April 13, 2026 [1] - Participation in the class action is not mandatory for recovery; shareholders can remain absent class members if they choose [1] - All legal representation is provided on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [1]

Core Viewpoint - A securities fraud class action lawsuit has been initiated against China Liberal Education Holdings Limited (CLEUF) for misleading investors during a specific class period, leading to significant financial losses for shareholders [1]. Group 1: Company Overview - China Liberal Education Holdings Limited (CLEUF) is facing legal action due to allegations of securities fraud, specifically related to undisclosed shares and misleading information provided to investors [1]. - The company reported 240 million previously undisclosed exchanged shares on January 29, 2025, resulting in a drastic stock price drop from $7.75 to $0.148 per share, marking a 98.1% loss [1]. Group 2: Legal Proceedings - The class action lawsuit claims that during the class period from January 22, 2025, to January 30, 2025, the defendants made materially false statements and failed to disclose adverse facts about the company's operations and prospects [1]. - Investors have until March 31, 2026, to file a lead plaintiff motion in this class action lawsuit [1].

Group 1 - The law firm Kahn Swick & Foti, LLC is investigating the proposed sale of Valaris Limited to Transocean Ltd, focusing on the adequacy of the price and process involved in the transaction [1] - Under the proposed terms, Valaris shareholders will receive 15.235 shares of Transocean stock for each share of Valaris they own [1] - KSF aims to determine if the consideration offered undervalues Valaris and whether the process leading to this transaction was adequate [1]

Core Viewpoint - Halper Sadeh LLC is investigating whether Clear Channel Outdoor Holdings, Inc. is obtaining a fair price for its shareholders in the proposed sale to Mubadala Capital and TWG Global for $2.43 per share in cash [1] Group 1: Investigation Details - The investigation focuses on whether Clear Channel and its board violated federal securities laws and/or breached fiduciary duties by failing to obtain the best possible price for shareholders [1] - Concerns include the fairness of the sales process and potential conflicts of interest, as well as the adequacy of disclosed material information for shareholders to evaluate the transaction [1] Group 2: Legal Representation - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, aiming to seek increased consideration, additional disclosures, or other relief for shareholders [1] - The firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [1]

Core Viewpoint - A class action lawsuit has been certified for all Vaxart shareholders, including those who participated in a previous partial settlement, with a deadline for exclusion set for March 11, 2026 [1][2] Group 1: Class Action Details - The lawsuit is certified as a class action in the United States District Court for the Northern District of California, related to Vaxart, Inc. securities litigation [1][2] - The class includes individuals or entities that purchased or acquired Vaxart common stock or options between June 25 and July 24, 2020, and were damaged [1][2] - Members who purchased shares on June 26 or June 29, 2020, are part of a Subclass, which has specific criteria for participation [1] Group 2: Legal Representation and Options - Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP are appointed as Class Counsel, representing the interests of the class members without requiring payment from them [1][2] - Class members have the option to either remain in the class, which binds them to court decisions, or request exclusion by the specified deadline, allowing them to pursue separate legal action [1][2] Group 3: Exclusion Process - To exclude from the class, individuals must submit a written request including personal details and proof of stock transactions by March 11, 2026 [1] - Excluded individuals will not be eligible for any recovery from the class action but can pursue their own claims against the Armistice Defendants [1][2]

Core Viewpoint - The Schall Law Firm is investigating potential fraud claims against PennyMac Financial Services, Inc. (PFSI) for possible violations of securities laws, particularly regarding misleading statements and undisclosed information [1] Financial Performance - PennyMac reported a pretax income of $37.3 million for its servicing segment in Q4 2025, a significant decrease from $157.4 million in the previous quarter and $87.3 million in Q4 2024 [1] - The company's retax income, excluding valuation-related items, was $47.8 million, reflecting a 70% decline from the prior quarter, primarily due to increased realization of mortgage servicing rights (MSR) cash flows as lower mortgage rates led to higher prepayment activity [1] Market Reaction - Following the announcement of its financial results, PennyMac's shares experienced a sharp decline of 33.3% the next day [1]

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against Ralliant Corporation following a significant non-cash goodwill impairment charge reported in their Q4 and full year 2025 results, which led to a substantial decline in share price [1]. Financial Performance - Ralliant Corporation reported a fourth quarter and full year 2025 results that included a $1.4 billion non-cash goodwill impairment charge in the Test & Measurement segment, primarily due to revised expectations for the EA Elektro-Automatik business [1]. - Following the announcement, Ralliant's share price fell by $17.89, or approximately 31.8%, from $56.28 to $38.39 on February 4, 2026 [1]. Legal Investigation - The investigation by Kirby McInerney LLP is focused on whether Ralliant Corporation and/or its senior management may have violated federal securities laws or engaged in unlawful business practices [1]. - As of now, no lawsuit has been filed, and the investigation is ongoing to determine the viability of potential claims under federal securities laws [1].

Group 1 - A class action lawsuit has been filed against Plug Power Inc. for allegedly misleading investors about its ability to receive and utilize a $1.66 billion loan from the U.S. Department of Energy (DOE) [1] - The lawsuit covers investors who purchased Plug Power securities between January 17, 2025, and November 13, 2025, and claims that the company overstated the likelihood of accessing the DOE loan funds [1] - Following the announcement of financial results on November 10, 2025, Plug Power's stock price fell by $0.09 per share, or 3.39%, closing at $2.53 per share [1] - On November 13, 2025, it was reported that Plug Power suspended its plans to construct six hydrogen production facilities, leading to a further decline in stock price by $0.48 per share, or 17.58%, closing at $2.25 per share [1] Group 2 - Robbins LLP is also involved in class action lawsuits for other companies, including Picard Medical, Inc. and Richtech Robotics Inc., indicating a broader trend of shareholder litigation in various sectors [2]